Non-Glutamatergic Clozapine Augmentation Strategies: A Review and Meta-Analysis

Abstract

Persistent negative symptoms and cognitive impairment are major clinical problems in the treatment of schizophrenia. There is no convincing evidence regarding the efficacy of augmentation of clozapine with a second antipsychotic, ethyl eicosapentaenoic acid (E-EPA), an antidepressant, a mood stabilizer or extract of Ginkgo biloba in clozapine-resistant schizophrenia. We present an overview of studies in which the potential clinical utility of the addition of non-glutamatergic agents to clozapine is assessed. We performed a meta-analysis on the efficacy of both risperidone and aripiprazole compared to placebo. We compared the effects of the addition of a second antipsychotic or an antidepressant to clozapine on positive, negative, overall and affective symptoms of schizophrenia in double-blind placebo-controlled trials.

Key words

schizophrenia - refractory - augmentation - clozapine

• References

• 1 Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012; 22: 165-182
• 2 Lieberman JA, Safferman AZ, Pollack S et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744-1752
• 3 Wolff-Menzler C, Hasan A, Malchow B et al. Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry 2010; 43: 122-129
• 4 Sommer IE, Begemann MJH, Temmerman A et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2012; 38: 1003-1011
• 5 Wang J, Omori IM, Fenton M et al. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev 2010; CD008125
• 6 Taylor DM, Smith L. Augmentation of clozapine with a second anti­psychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scandinavica 2009; 119: 419-425
• 7 Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009; CD006324
• 8 Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005; 20: 409-415
• 9 Hedges LV. Distribution theory for Glass’s estimator of effect size and related estimators. J Educ Stat 1981; 6: 107-128
• 10 Freudenreich O, Henderson DC, Walsh JP et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007; 92: 90-94
• 11 Shadish WR, Haddock CK. Combining estimates of effect size. In Cooper H, Hedges LV. eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994: 261-281
• 12 Kelley GA, Kelly KS. Statistical models for meta-analysis: a brief tutorial. World J Methodol 2012; 26: 27-32
• 13 Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 14 Rosenthal R. The ‘file drawer problem’ and tolerance for null effects. Psychol Bull 1979; 86: 638-641
• 15 Borenstein M, Hedges L, Higgins J et al. Comprehensive Meta Analysis Version 2. Engelwood, NJ: Biostat Inc; 2005
• 16 Gunduz-Bruce H, Oliver S, Gueorguieva R et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophr. Res. 2013; 143: 344-347
• 17 Fleischhacker WW, Heikkinen ME, Olié J-P et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13: 1115-1125
• 18 Peet M, Horrobin DF. (E-E Multicentre Study Group). A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7-18
• 19 Weiner E, Conley RR, Ball MP et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010; 35: 2274-2283
• 20 Mossaheb N, Sacher J, Wiesegger G et al. Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia. Eur Neuropsychopharmacol 2006; 16: 416
• 21 Shiloh R, Zemishlany Z, Aizenberg D et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569-573
• 22 Assion HJ, Reinbold H, Lemanski S et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008; 41: 24-28
• 23 Nielsen J, Emborg C, Gydesen S et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2012; 32: 173-178
• 24 Chang JS, Ahn YM, Park HJ et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-Controlled Trial. J Clin Psychiatry 2008; 69: 720-731
• 25 Muscatello MR, Bruno A, Pandolfo G et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011; 127: 93-99
• 26 Josiassen RC, Joseph A, Kohegyi E et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162: 130-136
• 27 Anil Yagcioglu AE, Kiviricik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005; 66: 63-72
• 28 Honer WG, Thornton AE, Chen EY et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472-482
• 29 Buchanan RW, Kirkpatrick B, Bryant N et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153: 1625-1627
• 30 Zoccali R, Muscatello MR, Cedro C et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004; 19: 71-76
• 31 Berk M, Gama CS, Sundram S et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol 2009; 24: 233-238
• 32 Lan GX, Li ZC, Li L. A randomized, placebo-controlled clinical trial of combined citalopram and clozapine in the treatment of negative symptoms of schizophrenia. Chin Mental Health J 2006; 20: 696-698
• 33 Mico U, Bruno A, Pandolfo G et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011; 26: 303-310
• 34 Emsley R, Myburgh C, Oosthuizen P et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596-1598
• 35 Small JG, Klapper MH, Malloy FW et al. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2003; 23: 223-228
• 36 Doruk A, Uzun O, Özşahin A. A placebo-controlled study of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2008; 23: 223-227
• 37 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19: 1-93
• 38 Brixner DI, Said Q, Corey-Lisle PK et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006; 40: 626-632
• 39 Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1386-1392
• 40 Fan X, Borba CP, Copeland P et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013; 127: 217-226